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by Karen E. Whitby and Thomas J. Flynn
The scientific community recently began to expand
its development ofinvitro test methods as alternatives
or adjuncts to standard toxicologic studies. Although
these tests could not completely replace whole animal
testing, the tiered approach that they provided did re-
duce the numberofchemicals that had tobe tested with
live animals. In vitro tests appear to offer several ad-
vantages over standard whole animal toxicologic ap-
proaches: theyuseeithernomammalsorasmallernum-
ber of mammals than the standard studies, and they
frequently can be completed more rapidly and with
fewer resources than standard in vivo methods. Under
certain circumstances, in vitro techniques also allow
control overthe dose thatreaches the site oftoxicologic
action, permit more rapid determination of the proxi-
mate toxicant, and facilitate determinations of the
mechanisms) of action.
One area oftoxicology that has been developing rap-
idly in recent years is that which seeks alternatives to
whole animal teratology testing. A number of systems
arecurrentlybeingdeveloped asscreensforteratogens.
Therefore, the Division of Toxicology in the Food and
Drug Administration's (FDA) Center for Food Safety
and Applied Nutrition convened an internal task force
to compile and review information on test systems cur-
rentlyunder development as adjuncts to classicalwhole
animal teratology testing procedures. The members
were chosen from staffscientists who represent abroad
range of scientific backgrounds and expertise.
The task force members began by reviewing the re-
port ofa consensus workshop (1) that evaluated several
invitrotestsystems aspotentialscreensforteratogens.
This consensus workshop was sponsored by the FDA,
the Interagency Regulatory LiaisonGroup, and the En-
vironmental Protection Agency. The task force agreed
to adopt the consensus workshop's definition ofin vitro
(i.e., "any system that employs test subjects otherthan
theintactpregnantmammal") and toinitiate literatures
searches to complement and expand the work that had
been completed by the consensus workshop.
On-line literature searches were conducted to obtain
pertinent articles published through spring 1986. Pa-
pers published after spring 1986 and foreign language
articles that could not be obtained and translated in a
timely manner were not reviewed. Papers that were
found to describe cytotoxicity assays, developmental
biology procedures, and other test systems that were
not specifically designated as teratology testing proce-
dures by their developers were excluded from further
consideration. More than 600 relevant journal articles
were identified, and these were divided into five sub-
categories forcriticalevaluation, asfollows: mammalian
whole embryo culture, rodent limb bud culture, embry-
onic organs in culture, cells in culture, and nonmam-
malian model systems.
Factors that were evaluated for each in vitro test
system included the end point(s) measured (e.g., bio-
chemical, morphological, or radiochemical); the diver-
sity ofcompounds testable inthe systembased onphys-
ical state or solubility; the presence of an endogenous
metabolic activation system or the feasibility of using
an exogenous activation system; the degree of system
standardization; the ability to correlate the in vitro re-
sults with any known in vivo findings; the test's utility
forproviding information on possible mechanisms ofac-
tion; and practical aspects such as the general complex-
ity of the techniques and equipment used to conduct
tests and the length oftime required to complete atest.
In addition to a critical review of the published litera-
ture, task force members obtained supplemental infor-
mation through personal communications with the au-
thors and other researchers. Such information included
the type of expertise required to conduct the in vitro
test, the resources (i.e., personnel and costs) required
to implement and use the systems, and the ongoing
validation efforts.
The task force members prepared written reviews
thatwere used to assessthe status ofinvitroteratology
testing as ofspring 1986. The followingreviews are the
reports ofthe taskforce. Anyopinions stated orimplied
in these articles are solely those ofthe task force mem-
bers. Theyarenotmeanttoreflectanycurrent orfuture
regulatory policies ofthe FDA.
We would like to acknowledge June Bradlaw, Benjamin Jackson,
David Hattan, and Carol Mapes for their review and commentary,
and Helen Reynolds, Norma Yess, and Lois Tomlinson for editorial
assistance.
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